Global MedTech startup Nutromics has raised the additional US $14 million for its wearable diagnostic platform.
This revolutionary investment is critical to Nutromics’ future expansion in Australia and the United States. Strategic investors included Dexcom Ventures, VU Venture Partners, and Artesian Investments.
This funding reflects a high degree of investor confidence in Nutromics’ technology, which will address some of healthcare’s most difficult conditions through the power of continuous diagnostic monitoring. Following in-vivo clinical trials, Nutromics intends to raise much additional funds in 2023.
Peter Vranes, Co-Founder and CEO, Nutromics, said, “We are aiming to cause a paradigm shift in diagnostic healthcare by essentially developing a lab-on-a-patch. A lack of timely and continuous diagnostic insights can strongly impact outcomes when dealing with critical disease states. With this strategic industry and VC investment in us, we see more confidence in our technology and hope to accelerate our growth, as the need for our platform in the lab diagnostic space is urgent.”
Nutromics is working on a wearable diagnostic platform that will employ DNA technology to track multiple targets in the human body with a single patch. This is the first technology of its sort that is both a platform and has been demonstrated to work on the human body. The DNA sensor technology will offer clinicians and patients with continuous and real-time diagnostic information on everything from hard-to-dose medications like vancomycin to biological markers for conditions like kidney disease.
Nutromics was established in 2017 and has received over US$20 million to date for its groundbreaking wearable diagnostic technology, including this recent acceleration round. This latest amount of funding will support the growth of clinical investigations, the expansion of the R&D team, and investment in both the Australian and US bases. Nutromics is one step closer to reaching their vision of a future with zero preventable deaths, due to the company’s exponential development over the previous year and this latest round of funding.
